HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Claudio Pisano Selected Research

namitecan

2/2014Synergistic antitumor activity of cetuximab and namitecan in human squamous cell carcinoma models relies on cooperative inhibition of EGFR expression and depends on high EGFR gene copy number.
12/2012Preclinical evaluation of the novel 7-substituted camptothecin Namitecan (ST1968) in paediatric tumour models.
7/2012The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
2/2010Efficacy of ST1968 (namitecan) on a topotecan-resistant squamous cell carcinoma.
7/2008Preclinical profile of antitumor activity of a novel hydrophilic camptothecin, ST1968.
6/2008Intracellular accumulation and DNA damage persistence as determinants of human squamous cell carcinoma hypersensitivity to the novel camptothecin ST1968.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Claudio Pisano Research Topics

Disease

58Neoplasms (Cancer)
09/2023 - 12/2002
19Carcinoma (Carcinomatosis)
10/2013 - 12/2002
6Glioblastoma (Glioblastoma Multiforme)
09/2023 - 12/2002
5Neoplasm Metastasis (Metastasis)
05/2014 - 04/2005
5Neuroblastoma
12/2012 - 10/2005
4Breast Neoplasms (Breast Cancer)
01/2017 - 02/2005
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
02/2014 - 06/2008
3Sarcoma (Soft Tissue Sarcoma)
03/2016 - 09/2011
3Rhabdomyosarcoma
03/2016 - 09/2010
3Leukemia
09/2014 - 07/2005
3Inflammation (Inflammations)
08/2012 - 02/2010
3Melanoma (Melanoma, Malignant)
06/2011 - 12/2002
3Peripheral Nervous System Diseases (PNS Diseases)
07/2005 - 11/2003
2Hematologic Neoplasms (Hematological Malignancy)
01/2023 - 02/2018
2Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated)
10/2020 - 09/2014
2Prostatic Neoplasms (Prostate Cancer)
01/2019 - 10/2012
2Acute Promyelocytic Leukemia
10/2017 - 11/2002
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
10/2017 - 09/2008
2Diabetic Nephropathies (Diabetic Nephropathy)
08/2012 - 01/2012
2Pancreatic Neoplasms (Pancreatic Cancer)
08/2012 - 04/2011
2Pathologic Neovascularization
06/2011 - 03/2010
2Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome)
01/2004 - 11/2002
2Myeloid Leukemia (Leukemia, Myelocytic)
01/2004 - 11/2002
1Communicable Diseases (Infectious Diseases)
02/2024
1Body Weight (Weight, Body)
11/2020
1Mesothelioma
11/2020
1Rheumatoid Arthritis
05/2020
1Experimental Arthritis
05/2020
1Hepatocellular Carcinoma (Hepatoma)
10/2019
1Glioma (Gliomas)
10/2018
1Ascites
02/2018
1Primary Effusion Lymphoma
02/2018
1Colorectal Neoplasms (Colorectal Cancer)
01/2018
1Retinal Degeneration
01/2017
1Retinitis Pigmentosa (Pigmentary Retinopathy)
01/2017
1Diabetic Retinopathy (Retinopathy, Diabetic)
01/2017
1Retinal Diseases
01/2017
1Disease Progression
01/2017
1Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
09/2014

Drug/Important Bio-Agent (IBA)

21RetinoidsIBA
02/2024 - 11/2002
153- (4'- hydroxy- 3'- adamantylbiphenyl- 4- yl)acrylic acidIBA
09/2023 - 03/2003
11Cisplatin (Platino)FDA LinkGeneric
01/2022 - 12/2002
11CamptothecinIBA
10/2013 - 12/2002
8heparanaseIBA
05/2014 - 04/2005
8ST 1481 (Gimatecan)IBA
04/2011 - 12/2002
6namitecanIBA
02/2014 - 06/2008
6Irinotecan (Camptosar)FDA LinkGeneric
12/2012 - 10/2005
5Tretinoin (Retinoic Acid)FDA LinkGeneric
10/2017 - 11/2002
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2012 - 02/2005
4Doxorubicin (Adriamycin)FDA LinkGeneric
03/2019 - 02/2005
4SST 0001IBA
01/2012 - 03/2011
4Topotecan (Hycamtin)FDA LinkGeneric
02/2010 - 12/2002
3Cytostatic AgentsIBA
10/2017 - 04/2003
3Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
05/2014 - 04/2005
3Proteins (Proteins, Gene)FDA Link
10/2013 - 09/2011
3Glycoside Hydrolases (Endoglycosidases)IBA
08/2012 - 04/2011
3AcidsIBA
07/2012 - 03/2003
3LigandsIBA
04/2011 - 01/2006
3Paclitaxel (Taxol)FDA LinkGeneric
01/2011 - 11/2003
3TubulinIBA
01/2011 - 05/2008
2adaroteneIBA
11/2020 - 04/2012
2ErbB Receptors (EGF Receptor)IBA
10/2019 - 02/2014
2CalciumIBA
10/2019 - 01/2004
2Temozolomide (Temodar)FDA LinkGeneric
10/2018 - 10/2017
2Morphine (MS Contin)FDA LinkGeneric
10/2017 - 01/2016
2Retinaldehyde (Retinal)IBA
01/2017 - 01/2017
2Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2013 - 07/2005
2IntegrinsIBA
10/2012 - 11/2010
2Heparitin Sulfate (Heparan Sulfate)IBA
08/2012 - 04/2011
2Peptides (Polypeptides)IBA
08/2012 - 11/2010
2Type I DNA Topoisomerases (Topoisomerase I)IBA
07/2012 - 04/2003
2Heparin (Liquaemin)FDA LinkGeneric
09/2011 - 03/2011
2Integrin alphaVIBA
01/2010 - 01/2006
2combretastatinIBA
10/2008 - 01/2007
2DNA (Deoxyribonucleic Acid)IBA
09/2008 - 07/2005
2Antineoplastic Agents (Antineoplastics)IBA
06/2005 - 11/2003
1Anti-Bacterial Agents (Antibiotics)IBA
02/2024
1DNA Polymerase I (Klenow Fragment)IBA
09/2023
1CeramidesIBA
10/2020
1Plant Preparations (Preparation, Plant)IBA
05/2020
1Propolis (Bee Bread)IBA
05/2020
1Sirolimus (Rapamycin)FDA Link
03/2019
1AnthracyclinesIBA
10/2018
1myristamidopropyl dimethylamineIBA
10/2018
1DOXO-EMCHIBA
10/2018
1DNA-Directed DNA Polymerase (Polymerases, DNA)IBA
01/2018
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2017
1Streptozocin (Streptozotocin)FDA Link
01/2017
1Nerve Growth Factor (NGF)IBA
01/2017
1CateninsIBA
01/2017
1acrylic acid (acrylate)IBA
03/2016
1Cetuximab (Erbitux)FDA Link
02/2014
1olaparibIBA
02/2014
12- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
10/2013

Therapy/Procedure

17Therapeutics
02/2024 - 02/2005
6Drug Therapy (Chemotherapy)
08/2021 - 05/2005
3Radiotherapy
10/2017 - 04/2011
2Aftercare (After-Treatment)
10/2013 - 09/2006
2Oral Administration
03/2003 - 12/2002
1Combined Modality Therapy
10/2017